Mon. 6 May 2024, 6:54am ET
Benzinga
Biotech, Earnings, News, Guidance, Health Care, General
Planned 2024 Financial Year Expenses and Capex
- R&D expenses: €2.4B-€2.6B
- SG&A expenses: €700M-€800M
- Capital expenditures for operating activities: €400M-€500M